Brand Name :
Generic Name :
What is this drug and what is it used for?
Indications and potential uses
Ocrevus is indicated for the treatment of adult patients with active relapsing forms of Multiple Sclerosis (MS).
Ocrevus is indicated for the treatment of adult patients with Primary Progressive Multiple Sclerosis (PPMS) to delay disease progression and reduce deterioration in walking speed.
How is this drug given?
The initial 600 mg dose (dose 1) is divided into two separate IV infusions, i.e. administered as two 300 mg infusions two weeks apart.
Subsequent Ocrevus doses are administered as a single 600 mg dose by IV infusion every 6 months.
A minimum interval of 5 months should be maintained between separate Ocrevus doses.
Possible side effects
Adverse reactions are presented in order of decreasing frequency.
Summary of ADRs occurring with Ocrevus in RMS or PPMS
Infections and infestations
Very common: Upper respiratory tract infection (RMS: 15.2%; PPMS: 12.1%), nasopharyngitis (PPMS: 24.1%; RMS: 14.9%), influenza (PPMS: 11.7%; RMS: 4.6%).
Common: Bronchitis, sinusitis, gastroenteritis, viral infection, oral herpes, respiratory tract infection, cellulitis, herpes zoster, conjunctivitis.
Respiratory, thoracic and mediastinal disorders
Common: Cough, catarrh.
General disorders and administration site conditions
Very common: Infusion-related reactions (PPMS: 40.1%; RMS: 34.3%) (symptoms reported as IRRs within 24 hours of infusion are described below as “Infusion-related reactions”).
Very common: IgM serum levels decreased.
Common: IgG serum levels decreased.
Treatment with Ocrevus resulted in a decrease in total immunoglobulins over the controlled-study period, mainly driven by a reduction in IgM.
Overall, the decrease in neutrophil count was transient in most cases (observed only once in a patient treated with Ocrevus) and grade 1 or 2 in severity.